📊 NDRA Key Takeaways
Is ENDRA Life Sciences Inc. (NDRA) a Good Investment?
Pre-revenue medical device company with $7M annual net losses and only $762K cash, implying critical 2-3 month funding runway. Despite 39% YoY loss improvement, the company faces severe liquidity risk without imminent revenue generation or capital raise. Fundamental business model remains unproven in electromedical apparatus sector.
ENDRA Life Sciences is pre-revenue with persistent operating losses and severely negative ROE/ROA, while holding minimal cash relative to its annual cash burn. Although losses improved YoY and the balance sheet has no long-term debt, liquidity is thin and additional financing is likely, leaving fundamentals weak until clear revenue traction emerges.
Why Buy ENDRA Life Sciences Inc. Stock? NDRA Key Strengths
- Zero long-term debt - no leverage risk
- Net losses improving 38.9% YoY - suggests operational progress
- Minimal capex requirements - asset-light development model
- Debt-free balance sheet with low liabilities
- Year-over-year improvement in net loss and EPS
- Asset-light operations with minimal capex
NDRA Stock Risks: ENDRA Life Sciences Inc. Investment Risks
- Critical cash position with ~2-3 months runway at current $5.2M burn rate
- Pre-revenue status with unvalidated commercialization pathway
- Severe negative profitability with -310.9% ROE and -182.4% ROA
- Imminent capital raise likely required, exposing shareholders to substantial dilution
- No demonstrated market traction or regulatory progress visibility
- High cash burn and limited cash implying short runway
- Elevated dilution risk from probable capital raises
- No revenue; uncertain commercialization and profitability timeline
Key Metrics to Watch
- Monthly cash burn rate and remaining runway
- Clinical trial enrollment/regulatory milestone announcements
- Capital raise activity and dilution impact
- Revenue recognition or pre-revenue metrics (pilot programs, partnerships)
- Insider transaction patterns indicating confidence
- Revenue
- Operating Cash Flow
ENDRA Life Sciences Inc. (NDRA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
ENDRA Life Sciences Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
NDRA Profit Margin, ROE & Profitability Analysis
NDRA vs Healthcare Sector: How ENDRA Life Sciences Inc. Compares
How ENDRA Life Sciences Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is ENDRA Life Sciences Inc. Stock Overvalued? NDRA Valuation Analysis 2026
Based on fundamental analysis, ENDRA Life Sciences Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
ENDRA Life Sciences Inc. Balance Sheet: NDRA Debt, Cash & Liquidity
NDRA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: ENDRA Life Sciences Inc.'s revenue has declined by 100% over the 5-year period, indicating business contraction. The most recent EPS of $-56.94 indicates the company is currently unprofitable.
NDRA Revenue Growth, EPS Growth & YoY Performance
NDRA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2019 | N/A | -$2.8M | N/A |
| Q2 2019 | N/A | -$1.8M | N/A |
| Q1 2019 | N/A | -$2.7M | N/A |
| Q3 2018 | N/A | -$908.9K | N/A |
| Q2 2018 | N/A | -$1.4M | N/A |
| Q1 2018 | N/A | -$741.6K | N/A |
| Q3 2017 | N/A | -$908.9K | N/A |
| Q2 2017 | $57.8K | -$729.1K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
ENDRA Life Sciences Inc. Dividends, Buybacks & Capital Allocation
NDRA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for ENDRA Life Sciences Inc. (CIK: 0001681682)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NDRA
What is the AI rating for NDRA?
ENDRA Life Sciences Inc. (NDRA) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 90% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are NDRA's key strengths?
Claude: Zero long-term debt - no leverage risk. Net losses improving 38.9% YoY - suggests operational progress. ChatGPT: Debt-free balance sheet with low liabilities. Year-over-year improvement in net loss and EPS.
What are the risks of investing in NDRA?
Claude: Critical cash position with ~2-3 months runway at current $5.2M burn rate. Pre-revenue status with unvalidated commercialization pathway. ChatGPT: High cash burn and limited cash implying short runway. Elevated dilution risk from probable capital raises.
What is NDRA's revenue and growth?
ENDRA Life Sciences Inc. reported revenue of $0.0.
Does NDRA pay dividends?
ENDRA Life Sciences Inc. pays dividends, with $0.0M distributed to shareholders in the trailing twelve months.
Where can I find NDRA SEC filings?
Official SEC filings for ENDRA Life Sciences Inc. (CIK: 0001681682) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NDRA's EPS?
ENDRA Life Sciences Inc. has a diluted EPS of $-8.93.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is NDRA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, ENDRA Life Sciences Inc. has a STRONG SELL rating with 90% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is NDRA stock overvalued or undervalued?
Valuation metrics for NDRA: ROE of -310.9% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy NDRA stock in 2026?
Our dual AI analysis gives ENDRA Life Sciences Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NDRA's free cash flow?
ENDRA Life Sciences Inc.'s operating cash flow is $-5.2M, with capital expenditures of $17.3K.
How does NDRA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -310.9% (avg: 15%), current ratio 1.29 (avg: 2).